AVRO VS DRRX Stock Comparison

Performance

AVRO
100/100

AVRO returned 78.43% in the last 12 months. Based on SPY's performance of -12.98%, its performance is above average giving it a score of 100 of 100.

DRRX
10/100

DRRX returned -58.52% in the last 12 months. Based on SPY's performance of -20.62%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

AVRO
88/100

4 analysts offer 12-month price targets for AVRO. Together, they have an average target of 0, the most optimistic target put AVRO at 0 within 12-months and the most pessimistic has AVRO at 0.

DRRX
58/100

3 analysts offer 12-month price targets for DRRX. Together, they have an average target of 0, the most optimistic target put DRRX at 0 within 12-months and the most pessimistic has DRRX at 0.

Technicals

AVRO
25/100

AVRO receives a 25 of 100 based on 14 indicators. 3 are bullish, 10 are bearish.

DRRX
11/100

DRRX receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Earnings

AVRO
10/100

AVRO has missed earnings 13 times in the last 20 quarters.

DRRX
10/100

DRRX has missed earnings 6 times in the last 20 quarters.

Profit

AVRO
10/100

Out of the last 20 quarters, AVRO has had 1 profitable quarters and has increased their profits year over year on 1 of them.

DRRX
13/100

Out of the last 20 quarters, DRRX has had 2 profitable quarters and has increased their profits year over year on 2 of them.

Volatility

AVRO
25/100

AVRO has had a lower than average amount of volatility over the last 12 months giving it a score of 25 of 100.

DRRX
46/100

DRRX has had a lower than average amount of volatility over the last 12 months giving it a score of 45 of 100.

Sentiment

AVRO

"Sentiment" not found for AVRO

DRRX
71/100

DRRX had a bullish sentiment score of 71.07% across Twitter and StockTwits over the last 12 months. It had an average of 8.27 posts, 8.63 comments, and 19.71 likes per day.

All score calculations are broken down here to help you make more informed investing decisions

AVROBIO, Inc. Common Stock Summary

Nasdaq / AVRO

Healthcare

Biotechnology

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Durect Corp Summary

Nasdaq / DRRX

Healthcare

Drug Manufacturers - Specialty & Generic

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Santen Pharmaceutical Co., Ltd. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

Power up your portfolio